

FROM: CORNERSTONE PHARMACEUTICALS, INC.  
1 Duncan Drive  
Cranbury, NY 08512  
[info@cornerstonepharma.com](mailto:info@cornerstonepharma.com)

Rubenstein Public Relations  
Contact: Adam Mazur / (212) 843-8073  
[amazur@rubensteinpr.com](mailto:amazur@rubensteinpr.com)

---

FOR IMMEDIATE RELEASE

## **CORNERSTONE PHARMACEUTICALS CHOSEN AMONG TOP 10 MOST INTERESTING ONCOLOGY PROJECTS**

**Cranbury, NJ, November 11, 2009** – Cornerstone Pharmaceuticals, Inc., the company behind CPI-613 - the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types - has been selected as one of the top 10 most interesting oncology projects available for partnering by Windhover Information, a provider of analysis of the healthcare industry to decision-makers at all levels for over 25 years.

As part of being selected, Cornerstone Pharmaceuticals President & COO Robert Rodriguez will present at Windhover's Therapeutic Area Partnerships meeting on November 17-19, 2009 at the Westin Copley Boston.

"We are very proud to have CPI-613 selected by Windhover as one of the top 10 most interesting oncology projects and look forward to the potential partnerships stemming from this distinction," remarked Cornerstone Pharmaceuticals CEO Dr. Robert Shorr. "It's also very exciting to have Bob Rodriguez, our President and COO, represent us at the upcoming meeting in Boston and I expect he will deliver an exceptional address."

Cornerstone is currently in the midst of recruiting patients with solid tumors to advance multiple Phase I/II human clinical trials of CPI-613, its lead drug to emerge from the company's Altered Energy Metabolism Directed (AEMD) technology platform. Trials are in progress both in the United States and in British Columbia, Canada.

Windhover selected and screened companies using a strict set of judging criteria for the Top 10 award representing what their committees considered the most attractive oncology opportunities the industry has to offer. Among the rigorous criteria Cornerstone Pharmaceuticals adhered to were: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.

"We are thrilled that Cornerstone Pharmaceuticals' CPI-613 project achieved those high standards," added Shorr.

### **About TA Partnerships**

Windhover Information's 4th Annual *Therapeutic Area Partnerships* is the industry's most targeted and efficient partnering meeting for life science companies seeking partnerships in the top therapeutic areas: Oncology, Cardiovascular/Metabolic, Neuroscience and Inflammatory Diseases. Decision-makers (business development and R & D) focusing on these therapeutic categories can meet to develop strategic alliances between their companies. Also, attendees enjoy the personal and interactive setting that combines company presentations, 1:1 meetings and networking functions.

### **About Windhover**

Windhover Information Inc., an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see [www.windhover.com](http://www.windhover.com).

### **About CPI-613**

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types. Cornerstone Pharmaceuticals is currently recruiting patients with solid tumors to advance multiple Phase I/II human clinical trials of CPI-613, CPI-613 is being evaluated in a Phase I/II single agent trial for patients who have failed all other therapy as well as in a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients determined to be treated with gemcitabine. Pancreatic cancer, like many solid tumors, typically has a poor prognosis, spreads rapidly and often goes undetected in its early stages. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.

### **About Cornerstone Pharmaceuticals**

Cornerstone Pharmaceuticals, Inc. is a privately held pharmaceutical company singularly focused on the discovery and development of innovative cancer therapies that exploit the metabolic pathways that are common to different cancer types but different from normal cells and tissues. This unique approach, i.e. understanding and addressing what is similar to multiple cancer types rather than the differences between each, offers a significant opportunity to make a profound impact on the clinical treatment of a variety of cancers.

Cornerstone's AEMD technology platform was established on cancer metabolism research performed in the laboratories of Paul M. Bingham, Ph.D. and Zuzana Zachar, Ph.D., at the State University of New York at Stony Brook, Stony Brook, NY.

Cornerstone has offices and laboratory facilities in Cranbury, New Jersey and Stony Brook, New York. For further information, please call (212) 843-8073 or email [amazur@rubensteinpr.com](mailto:amazur@rubensteinpr.com) or log onto <http://www.cornerstonepharma.com>.

###